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ABSTRACT
Objective Liver biopsy is still needed for fibrosis 
staging in many patients with non- alcoholic fatty liver 
disease. The aims of this study were to evaluate the 
individual diagnostic performance of liver stiffness 
measurement by vibration controlled transient 
elastography (LSM- VCTE), Fibrosis-4 Index (FIB-4) and 
NAFLD (non- alcoholic fatty liver disease) Fibrosis Score 
(NFS) and to derive diagnostic strategies that could 
reduce the need for liver biopsies.
Design Individual patient data meta- analysis of 
studies evaluating LSM- VCTE against liver histology 
was conducted. FIB-4 and NFS were computed where 
possible. Sensitivity, specificity and area under the 
receiver operating curve (AUROC) were calculated. 
Biomarkers were assessed individually and in sequential 
combinations.
Results Data were included from 37 primary studies 
(n=5735; 45% women; median age: 54 years; median 
body mass index: 30 kg/m2; 33% had type 2 diabetes; 
30% had advanced fibrosis). AUROCs of individual LSM- 
VCTE, FIB-4 and NFS for advanced fibrosis were 0.85, 0.76 
and 0.73. Sequential combination of FIB-4 cut- offs (<1.3; 
≥2.67) followed by LSM- VCTE cut- offs (<8.0; ≥10.0 kPa) 
to rule- in or rule- out advanced fibrosis had sensitivity and 
specificity (95% CI) of 66% (63–68) and 86% (84–87) 
with 33% needing a biopsy to establish a final diagnosis. 
FIB-4 cut- offs (<1.3; ≥3.48) followed by LSM cut- offs 
(<8.0; ≥20.0 kPa) to rule out advanced fibrosis or rule in 
cirrhosis had a sensitivity of 38% (37–39) and specificity 
of 90% (89–91) with 19% needing biopsy.
Conclusion Sequential combinations of markers with a 
lower cut- off to rule- out advanced fibrosis and a higher 
cut- off to rule- in cirrhosis can reduce the need for liver 
biopsies.
INTRODUCTION
Non- alcoholic fatty liver disease (NAFLD) is the 
hepatic manifestation of the metabolic syndrome 
with high prevalence worldwide.1 Most patients 
remain asymptomatic for long periods of time 
(years/decades) with slowly progressive disease, but 
Significance of this study
What is already known on this subject?
 ► Patients with non- alcoholic fatty liver disease 
(NAFLD) and advanced fibrosis (F3–4) are at 
risk of disease progression and adverse clinical 
outcomes.
 ► Non- invasive tests with predefined cut- offs are 
used as screening biomarkers to identify those 
at low risk of advanced fibrosis who can be 
safely managed in primary care.
 ► Liver biopsy is still needed in secondary care to 
further identify those with cirrhosis who would 
benefit from surveillance for hepatocellular 
cancer and screening for oesophageal varices.
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a minority2 progress to cirrhosis, liver failure and hepatocellular 
carcinoma (HCC).
NAFLD comprises several histological features ranging from 
simple steatosis to steatosis with lobular inflammation and 
ballooned hepatocytes (steatohepatitis), both of which can 
be accompanied by varying degrees of fibrosis. The currently 
accepted reference standard for diagnosing NAFLD is liver 
biopsy as its diagnostic features are based on histology.3 Liver 
biopsy, however, is invasive and carries a risk of complications,4 
is limited by sampling variability5 and high observer dependent 
variability in pathological reporting.6 7
NAFLD is often diagnosed after incidental findings of elevated 
liver transaminases on blood tests, or liver steatosis or cirrhosis 
on imaging. One challenge clinicians face is to identify which of 
these patients are at high risk of progression or clinical outcomes, 
as they would benefit from specialist follow- up. There is now 
substantial evidence showing that those with at least advanced 
fibrosis (F3–4) are at higher risk of liver- related events in later 
life.8–10
A large body of evidence also exists on how non- invasive tests 
(NITs) could be used to risk- stratify patients for the presence of 
advanced fibrosis. These approaches usually involve sequential 
application of two NITs, with the first tier of a simple, inex-
pensive, serum- based test performed in the community (eg, 
Fibrosis-4 Index (FIB-4) or NAFLD Fibrosis Score (NFS)), 
followed by a second tier of liver stiffness measurement (LSM) 
(eg, vibration controlled transient elastography: VCTE), or a 
proprietary serum- based test (eg, enhanced liver fibrosis test; 
ELF). A lower and an upper threshold are usually used in each 
tier of testing to rule out (those with a NIT result less than the 
lower threshold) or rule in (those with a NIT result more than 
the upper threshold) patients at high risk of advanced fibrosis. 
Patients with indeterminate results in both tiers of testing would 
need a liver biopsy for risk stratification. The main value of these 
approaches lies in their high negative predictive value to rule out 
patients with low risk of advanced fibrosis who can be safely 
managed in primary care.
Despite the increasing evidence to support these approaches, 
some aspects of their application require further clarifications. 
First, there is no consensus on which NIT thresholds to use for 
this purpose. For example, FIB-4 upper cut- offs of 3.2511 and 
2.6712 have been described, while other investigators omit the 
FIB-4 upper cut- off altogether.13 There is also some uncertainty 
about the performance of NITs in specific patient subgroups, 
such as those with diabetes or obesity. Furthermore, for patients 
who are ruled in as being at high risk of advanced fibrosis (F3–4), 
liver biopsy is often needed to identify those with cirrhosis who 
would need surveillance for HCC.14 Developing approaches that 
can minimise the need for liver biopsy in secondary care is there-
fore an area of unmet need.
To address these problems, we conducted an individual 
patient data meta- analysis (IPDMA) with three main aims: (1) 
to evaluate the performance of LSM- VCTE and compare it to 
the performance of FIB-4 and NFS as screening tests to rule out 
advanced fibrosis; (2) to evaluate NIT combination strategies to 
minimise the number of cases that would need a liver biopsy in 
secondary care; (3) to explore factors that influence diagnostic 
accuracy.
METHODS
This IPDMA was reported in accordance with the recommen-
dations of the Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses- IPD Statement15 and was registered as 
PROSPERO CRD42019157661.
Criteria for considering studies for the IPD meta-analysis
Patients
Studies reporting data on adults (≥18 years) with NAFLD and 
paired liver histology and LSM- VCTE were eligible. When 
studies reported study groups of participants with unselected 
aetiologies, only IPD of those with NAFLD were sought.
Index tests
The index test of main interest was LSM- VCTE performed 
with FibroScan (Echosens, France). Results for serum- based 
biomarkers NSF,16 FIB-4,17 aspartate aminotransferase (AST) to 
alanine aminotransferase (ALT) ratio18 and AST- to- platelet ratio 
index (APRI)19) were also computed where data were available. 
Online supplemental table 1 summarises the definition of NITs 
considered in this IPDMA.
Universally accepted cut- offs for diagnosing different groups 
of fibrosis stages do not exist (several suggested cut- offs are 
presented in online supplemental table 2). For LSM- VCTE, <7.9 
kPa and ≥9.6 kPa are the most used for respectively ruling out 
and in, advanced fibrosis.20
Reference standard
Only studies reporting histological classification of liver fibrosis 
based on the non- alcoholic steatohepatitis Clinical Research 
Network (NASH CRN) staging system were considered.21
Target conditions
Advanced fibrosis (F3–4) and cirrhosis (F4) were the target 
conditions of interest. To fulfil the aims of the study, cut- offs 
Significance of this study
What are the new findings?
 ► Existing non- invasive tests cut- offs are validated for their use 
as screening biomarkers to rule out advanced fibrosis in a 
study group of 5735 patients.
 ► The sequential combination of Fibrosis-4 Index (FIB-4) 
(<1.3; ≥2.67) and liver stiffness measurement by vibration 
controlled transient elastography (LSM- VCTE) (<8.0 kPa; 
≥10.0 kPa) which is increasingly used in routine practice has 
a false negative rate of 9% for advanced fibrosis.
 ► The diagnostic performance of LSM- VCTE for advanced 
fibrosis is influenced by biopsy quality, body mass index and 
presence of type 2 diabetes.
 ► An algorithm combining FIB-4 and LSM- VCTE sequentially 
with lower cut- offs to rule out advanced fibrosis (FIB-4 
<1.3; LSM- VCTE <8.0 kPa) and with upper cut- offs to rule- 
in and positively diagnose cirrhosis without the need for 
liver biopsy with specificity of 95% (FIB-4 ≥3.48; LSM- VCTE 
≥20.0 kPa) or 98% (FIB-4 ≥4.63; LSM- VCTE ≥28.0 kPa) can 
reduce the need for liver biopsies from 33% to 19% or 24%, 
respectively.
How might it impact on clinical practice in the foreseeable 
future?
 ► The non- invasive test cut- offs for the diagnosis of cirrhosis 
can be incorporated into clinical practice as they have been 
validated in a large group of patients.
 ► Application of these cut- offs can lead to a decrease in the 
need for liver biopsies in secondary care.
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were selected to rule out or rule in advanced fibrosis, and to rule 
out advanced fibrosis or rule in cirrhosis.
Study design
All study designs were considered if they were reporting on 
patients with NAFLD undergoing both liver biopsy and LSM- 
VCTE within 6 months. No language restrictions were applied.
Establishing collaborations
Authors of eligible studies were contacted by email and reminders 
were sent if a response was not received within 2 weeks. Only 
data from studies that received ethical approval were used. Addi-
tional ethical approval was not sought for the meta- analysis as 
only anonymised data were provided.
Data verification
Range checks of measurement values provided for individual 
patients were carried out and authors were asked to provide 
clarifications where necessary. Missing data were queried until 
received or confirmed as unavailable. Missing data were handled 
in the analysis by pairwise deletion.
LSM- VCTE with median stiffness ≥7.1 kPa and IQR- to- 
median LSM ratio >30% were considered unreliable.22 These 
were included in the main analysis and were later compared in 
a subgroup analysis to reliable measurements, to assess whether 
they can be reliably used to diagnose advanced fibrosis.
Authors were provided with a template table of required data 
(online supplemental table 3) and were asked to deduplicate data 
were possible. We also checked for duplicate entries and where 
identified these were removed.
Data analysis
Quality and bias assessment
The quality of studies was assessed using the Quality Assessment 
of Diagnostic Accuracy Studies tool (QUADAS-2).23
IPD meta-analysis
The original data sets were merged, a study identification vari-
able was added, and descriptive statistical analysis of the data 
sets was conducted. Dichotomous variables are displayed as 
percentages. Continuous variables are reported as means with 
SD, or medians with IQRs according to the distribution of the 
data.
Analyses were done per protocol, as we did not have infor-
mation on failed LSM- VCTE. To express the diagnostic perfor-
mance of NITs, non- parametric, empirical receiver operating 
characteristic (ROC) curves were constructed for the target 
conditions of interest. Diagnostic performance was expressed as 
the area under the ROC curve (AUROC) with 95% CI, based on 
De Long’s method. AUROCs were compared using De Long’s 
test statistic.
Thresholds to maximise the Youden index (ie, sensitivity+spec-
ificity−1), for 90% sensitivity, and for 90% specificity were 
reported. The diagnostic performance of previously published 
cut- offs was also evaluated. Sequential combinations of serum 
biomarkers and LSM- VCTE were evaluated, by computing sensi-
tivity, specificity and proportions of misclassified and indetermi-
nate patients.
Positive and negative predictive values (PPV and NPV) were 
estimated for prevalences within the range of those reported in 
the original studies. The number of false positive and false nega-
tive results for 100 theoretical cases was also reported.
The main analysis was conducted to maximise data for each 
NIT. For a valid comparison of the performance of NITs, a sepa-
rate analysis was conducted in the subgroup of patients where all 
three of VCTE, FIB-4 and NFS were available in each participant.
To fulfil the aim of developing testing strategies that reduce 
the number of patients in need of a liver biopsy, lower cut- offs 
for ruling out advanced fibrosis and upper cut- offs for ruling 
in cirrhosis were used. The rationale for this approach is illus-
trated in online supplemental figure 1. The upper cut- offs for 
identifying cirrhosis were chosen at 95% and 98% specificity 
in a derivation set and tested in a validation set. Derivation and 
validation sets were obtained by random sampling from the IPD 
study group in a 3:2 ratio. These upper cut- offs were combined 
with lower cut- offs from the literature for ruling out advanced 
fibrosis and the algorithm was tested in the whole IPD study 
group. For ease of reference, we also examined the cut- offs of 
8 kPa and 10 kPa (corresponding to the most common VCTE 
cut- offs in the literature of 7.9 kPa and 9.6 kPa rounded to the 
nearest integer) and also rounded our cirrhosis cut- offs to the 
nearest integer to facilitate application in clinical practice.
Only test- positive and test- negative patients were included in 
the calculation of diagnostic performance indices, and patients 
in the indeterminate group were excluded from calculations.
Subgroup analysis was performed according to biopsy length 
(<20 mm, ≥20 mm), number of portal tracts in biopsy samples 
(<11, ≥11), biopsy quality (intermediate: 10 mm ≤length <20 
mm; high: length ≥20 mm and ≥11 tracts), age (four quartiles), 
sex, body mass index (BMI; BMI <25 kg/m2, 25 kg/m2≤ BMI 
<30 kg/m2, BMI ≥30 kg/m2), presence of type 2 diabetes mellitus 
(T2DM), continent of provenance (Europe, Asia), probes used 
(M, XL), reliability criteria for LSM- VCTE (reliable (median 
LSM <7.1 kPa or median LSM ≥7.1 kPa and IQR/median LSM 
<0.30) vs unreliable (median LSM ≥7.1 kPa and IQR/median 
LSM ≥0.30)22 ; reliable (IQR/median LSM <0.30) vs unreliable 
(IQR/median LSM ≥0.30)), and aminotransferase levels (ALT or 
AST<40, 40≤ALT or AST<100, ALT or AST≥100; ALT<40 
and AST<40, ALT≥40 or AST≥40.
All statistical analyses were performed using R (V.1.2.1335, R 
Foundation for Statistical Computing, Vienna, Austria) with the 
pROC package24 25; 95% CIs were calculated using 500 strati-
fied bootstrap replicates using the boot package.26 27
VCTE probe types
The analysis to account for probe type is described in the online 
supplemental materials.
Patient and public involvement
Patients and the public were not involved in the conduct of this 
study as there was no direct patient participation in the study.
RESULTS
Search process and data collection
Ten thousand three hundred ninety- two articles were identified 
in a search performed for a larger systematic review evaluating 
the diagnostic performance of LSM- VCTE and other index tests 
for the staging of fibrosis and diagnosis of NASH in adult patients 
with NAFLD. After removing duplicates, and screening titles, 
abstracts, and full texts, 59 studies examining VCTE were iden-
tified. The authors of 37 studies shared useable data (figure 1). 
Authors of more than one study supplied data in a single dataset 
and, overall, we received 30 data sets including data from 6571 
patients. After removing duplicates (n=628) and patients with 
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missing biopsy (n=14) or LSM- VCTE (n=194) data, the final 
dataset consisted of 5735 unique patients.
Study and population characteristics
The characteristics of the 30 data sets are summarised in table 1. 
Studies were conducted in Europe (67%), Asia (40%) and 
Australia (3%). Data availability is shown in online supplemental 
table 3. FIB-4 and NFS were determined in 5393 (94%) and 
3248 (57%) cases, respectively. Median age was 54 years, 2570 
(45%) patients were women, 33% had diabetes and 43% had 
BMI ≥30 kg/m2. Overall, 30% had advanced fibrosis and 11% 
had cirrhosis. Details of the IPD study group are included in 
table 2, and online supplemental tables 4 and 5.
Study quality
The methodological quality of the studies assessed with the 
QUADAS-2 tool is summarised in online supplemental figures 
2 and 3. Only one study had low risk of bias or low applica-
bility concerns in all QUADAS-2 domains.28 The flow and timing 
domain were judged to have high risk or unclear risk of bias in 
65% of studies, as these either excluded technical failures from 
their final diagnostic performance analysis or did not report 
them.
Validating the diagnostic performance of LSM by VCTE and 
serum-based tests for detecting advanced fibrosis
LSM- VCTE, FIB-4, NFS, APRI and AST/ALT had corresponding 
AUROCs of 0.85, 0.76, 0.73, 0.70, 0.64 for identifying advanced 
fibrosis (table 3), and 0.90, 0.80, 0.78, 0.72, 0.69 for the iden-
tification of cirrhosis (online supplemental table 6). LSM- VCTE 
performed significantly better (p<10−15) in detecting both 
advanced fibrosis and cirrhosis than all serum- based tests. This 
relationship was preserved when performing a head- to- head 
comparison of LSM- VCTE, FIB-4 and NFS in the same group of 
patients (online supplemental tables 7 and 8).
When considering cut- offs from the literature, we evaluated 
lower and higher cut- offs separately. For any given test, as would 
be expected, low thresholds yielded higher sensitivity and high 
thresholds were associated with higher specificity (online supple-
mental table 9). Indicative PPV and NPV are also provided for 
the range of prevalences (5%–50%) reported in the primary 
studies (online supplemental tables 10–14).
APRI and AST/ALT ratio had only modest diagnostic perfor-
mance for advanced fibrosis (AUROC ≤0.70, table 3), and were 
therefore not considered further.
None of the thresholds regarded in isolation resulted in both 
a high sensitivity (≥80%) and high specificity (≥80%) (figure 2, 
table 3, online supplemental tables 9 and 15, and online supple-
mental figure 4). Therefore, we explored the use of a lower and 
an upper cut- off. LSM- VCTE literature cut- offs performed well 
in only two cases (<7.1 kPa and ≥14.1 kPa: 83% sensitivity, 
90% specificity; and <7.9 kPa and ≥9.6 kPa: 84% sensitivity, 
78% specificity), while for other LSM- VCTE, NFS and FIB-4 
thresholds a high specificity was observed (FIB-4: 91% for <1.3 
and ≥2.67, 95% for <1.3, ≥3.25) but sensitivity was <60% 
(table 4). In addition, the proportion of indeterminate cases was 
>30% for serum- based NITs. Threshold pairs derived from the 
IPD study group did not reduce the proportion of misclassified 
and indeterminate patients seen with literature- based threshold 
pairs (table 4).
We further evaluated the performance of LSM- VCTE, FIB-4 
and NFS to diagnose advanced fibrosis in sequential combi-
nations of serum- based NITs and LSM- VCTE. When selecting 
threshold combinations for FIB-4 and NFS available in the 
literature (<1.3 & ≥2.67,<1.3 & ≥3.25 for FIB-4;<−1.455 
& ≥0.676 for NFS) and pairing them with the best threshold 
pair for LSM- VCTE (<7.9 kPa & ≥9.6 kPa, identified as the 
one with highest sensitivity and lowest indeterminate propor-
tion), the proportion of patients in the indeterminate group was 
5%. While both the FIB-4+LSM VCTE and NFS+LSM VCTE 
sequential combinations had specificity >80%, their sensitivity 
was ≤80% (table 5). A better sensitivity was reached by using 
thresholds derived from the IPD study group (<0.88 & ≥2.31 
for FIB-4;<−2.55 & ≥0.28 for NFS), but the proportion of 
indeterminate cases was near 20% in those cases and the propor-
tions of patients needing LSM- VCTE was also larger than when 
using literature cut- offs (table 5).
Algorithms to minimise the need for liver biopsy
In the derivation set, the cut- offs for 95% and 98% specificity 
for the diagnosis of cirrhosis were respectively 20.4 kPa and 27.6 
kPa for LSM- VCTE, 3.48 and 4.63 for FIB-4 and 1.01 and 1.57 
for NFS. These cut- offs performed similarly in the validation set 
(online supplemental tables 16 and 17).
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta- 
Analyses flow chart illustrating the identification and selection process 
for studies finally included in this individual patient data meta- analysis. 
IPD, individual patient data; LSM, liver stiffness measurement; VCTE, 
vibration controlled transient elastography.











5Mózes FE, et al. Gut 2021;0:1–14. doi:10.1136/gutjnl-2021-324243
Hepatology
Algorithms combining FIB-4 (lower cut- off of 1.3 as 
described in the literature and upper cut- offs of 3.48 and 
4.63 as described above) and LSM by VCTE (lower cut- off 
rounded to 8.0 kPa and upper cut- offs rounded to 20.0 kPa 
and 28.0 kPa, as described above) were then compared with 
the traditional way of applying these tests, also with rounded 
cut- offs for LSM by VCTE (8 kPa and 10 kPa) (figure 3). This 
approach increased the number of patients requiring a LSM 
Table 1 Details of individual patient data included in this meta- analysis
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(from 34% to 40% and 44%) but decreased the number of 
patients needing liver biopsy (from 33% to 19% and 24% 
when using the 95% and 98% specificity cut- offs, respec-
tively) (online supplemental table 18 and figure 3).
Subgroup and sensitivity analyses
In subgroup analysis for the diagnosis of advanced fibrosis 
(online supplemental table 19), NITs performed better 
in patients with lower BMI (AUROCs LSM- VCTE: 0.91, 
p<0.005; FIB-4: 0.81, p<0.001; NFS: 0.76, p<0.025), 
without T2DM (LSM- VCTE: 0.87, p<10−6; FIB-4: 0.77, 
p<0.01), and with biopsies shorter than 20 mm (LSM- 
VCTE: 0.87, p<0.005; FIB-4: 0.80, p<0.001; NFS: 0.79, 
p<0.05), or with fewer than 11 portal tracts (LSM- VCTE: 
0.86, p=0.01; FIB-4: 0.79, p=0.04; NFS: 0.78, p<0.005). 
Diagnostic performance was also lower in patients in the 
youngest age quartile (<43 years, AUROC: 0.58, p<0.001) 
and in women (AUROC: 0.71, p=0.03) for NFS, while 
continent of provenance did not have a significant effect for 
any NITs. In patients with normal levels of ALT (ALT<40) 
FIB-4 performed worse (AUROC: 0.73) than in patients 
with ALT≥40 and ALT<100 (AUROC: 0.77, p<0.01). NFS 
Table 2 Demographic details of the entire cohort, and patients 







Females (%) 45 43 48
BMI ≥30 kg/m2 (%) 43 45 53
Waist circumference (cm) 103 (15) 102 (15) 106 (14)
Diabetes (%) 33 30 58
Age (years)* 54 (19) 50 (19) 59 (14)
BMI (kg/m2)* 30 (7) 29 (8) 30 (7)
Biopsy data
Steatosis
S0/S1/S2/S3 (%) 3/35/36/26 3/36/36/25 2/32/38/28
Ballooning
B0/B1/B2 (%) 24/47/29 30/49/21 10/45/45
Inflammation
I0/I1/I2/I3 (%) 13/60/24/3 17/62/20/1 5/55/34/6
NAS score† 4 (2) 4 (2) 5 (1)
NASH (%) 50 43 67
Liver function tests
ALT (IU/L)* 55 (48) 53 (48) 60 (48)
AST (IU/L)* 40 (30) 36 (25) 50 (34)
Platelets (×109/L)† 230 (72) 241 (67) 205 (75)
Albumin (g/L)† 43 (9) 43 (7) 43 (13)
GGT (IU/L)* 69 (87) 62 (78) 87 (102)
NITs
LSM (kPa)* 10.7 (6.1) 6.7 (3.5) 13.3 (12.0)
FIB-4* 1.7 (1.2) 1.1 (0.9) 1.9 (1.7)
NFS† −1.5 (1.7) −1.9 (1.6) −0.6 (1.8)
APRI* 0.6 (0.4) 0.4 (0.3) 0.6 (0.6)
AST/ALT* 0.8 (0.4) 0.7 (0.4) 0.8 (0.5)
*Data are reported as median (IQR).
†Data are reported as mean (SD).
ALT, alanine aminotransferase; APRI, AST- to- platelet ratio index; AST, aspartate 
aminotransferase; BMI, body mass index ; FIB-4, Fibrosis-4 Index; GGT, gamma- 
glutamyltransferase; LSM, liver stiffness measurement; NAS, NAFLD activity score; 
NASH, non- alcoholic steatohepatitis; NFS, NAFLD (non- alcoholic fatty liver disease) 
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performed better in patients with AST<40 (AUROC: 0.76), 
than in patients with AST≥100 (AUROC: 0.65, p<0.01). 
FIB-4 performed better in patients with at least one abnormal 
aminotransferase measurement (AUROC: 0.72, p=0.014). 
For cirrhosis, the trends were similar, except that for the 
diagnosis of cirrhosis, LSM by VCTE performed better in 
the youngest age group (AUROC: 0.97, p<10−4) and NIT 
diagnostic performance was independent of aminotransferase 
levels (online supplemental table 20).
The diagnostic performance of LSM- VCTE was significantly 
lower in patients with unreliable LSMs (p<10−8; both for 
advanced fibrosis and cirrhosis) when applying the Boursier- 
criteria,22 but not when only considering IQR/median LSM 
<0.30. The proportion of unreliable results was 12% both in 
the advanced fibrosis and cirrhosis groups (online supplemental 
table 21).
There was no difference in the diagnostic performance of 
LSM- VCTE between the M and XL probes in the subgroup 
of patients who had undergone LSM by both probes (online 
supplemental table 22).
In a sensitivity analysis of patients with LSM matched to BMI 
(only M probe measurements if BMI <30 kg/m2 and only XL 
probe measurements if BMI ≥30 kg/m2), there was no signif-
icant difference between the diagnostic performance of LSM- 
VCTE when comparing to the entire IPD study group (online 
supplemental table 23).
Figure 2 Distribution of sensitivities and specificities over the possible threshold ranges for liver stiffness measurement (LSM) by vibration 
controlled transient elastography (VCTE) (A), Fibrosis-4 Index (FIB-4) (B) and NAFLD (non- alcoholic fatty liver disease) Fibrosis Score (NFS) (C) when 
considering the diagnosis of advanced fibrosis. Insets show the distribution of cut- offs identified from the literature. Horizontal dashed lines are 
representing the minimum acceptable criteria for considering a test as having high sensitivity (≥80%) and high specificity (≥80%).











8 Mózes FE, et al. Gut 2021;0:1–14. doi:10.1136/gutjnl-2021-324243
Hepatology
DISCUSSION
Through an extensive collaboration network with authors of 
primary studies we were able to collect the largest dataset of 
its kind ever to be reported on. This includes a diverse set of 
study groups from Europe, Asia, and Australia, 30% of whom 
had advanced fibrosis. We believe that our findings are therefore 
relevant for patients typical of secondary care in these territories 
and may be applied in the development of new strategies or in 
the consolidation of existing practices in evaluating patients for 
referral to secondary care.
A few studies evaluated the diagnostic performance of LSM- 
VCTE and other NITs, but most report on fewer than 500 
patients. One similarly large study reported on patients screened 
for inclusion in clinical trials, where the prevalence of advanced 
fibrosis was 71%,29 making it difficult to make generalisations 
about its applicability in routine practice or compare its results to 
ours. A smaller study with 1073 patients with NAFLD of whom 
29% had advanced fibrosis30 examined the diagnostic perfor-
mance of LSM by VCTE. The authors of that study reported 
AUC and specificity values similar to our findings, however they 
reported increased sensitivity. Other smaller studies reported 
similar prevalence of advanced fibrosis and similar AUROCs for 
LSM- VCTE.31–34
Overall, the diagnostic performance of LSM- VCTE for 
advanced fibrosis was good (AUROC=0.85), while that of FIB-4 
and NFS in the same group was moderate (AUROC=0.76 for 
FIB-4, AUROC=0.73 for NFS). None of the studied NITs had 
both sufficiently high sensitivity and specificity (≥80%) when 
used with single cut- offs. Diagnostic performance was higher 
for detecting cirrhosis, as reported in previous studies.31 35 36 
LSM- VCTE had the highest sensitivity and specificity, both in 
the case of a single cut- off (9.1 kPa obtained by maximising the 
Youden index; 77% and 78%) and for two cut- offs (<7.4 kPa 
& ≥12.1 kPa; 84% and 87%). Of the LSM- VCTE cut- off pairs 
tested,<7.1 kPa and ≥14.1 kPa, first published by Eddowes et 
al.,31 performed well for advanced fibrosis, with sensitivity of 
83% and specificity of 90%, but with a proportion of 39% of 
patients ending up with an indeterminate result, similar to 41% 
indeterminate patients reported in the original paper.31
LSM- VCTE thresholds identified in our study group (<9.1 
kPa; <7.4 kPa & ≥12.1 kPa) were similar to thresholds reported 
in the literature (<9.9 kPa; <7.1 kPa & ≥14.1 kPa, <7.9 kPa 
& ≥9.6 kPa). However, thresholds for FIB-4 (<1.44; <0.88 & 
≥2.31) and NFS (<−1.39; <−2.55 & ≥0.28) defined in our 
IPD study group spanned a wider range than those reported in the 
literature (<1.3 & ≥2.67 or <1.3 & ≥3.25 for FIB-4;<−1.455 
& ≥0.676 for NFS).
Our findings are in line with the existing literature suggesting 
that sequential combinations of NITs increase sensitivity and 
specificity.29 Additionally, we have found NFS+LSM VCTE 
and FIB-4+LSM VCTE combinations to have similar sensitivity 
and specificity as recently reported by Boursier et al.37 Such 
combined testing strategies can reduce the number of indeter-
minate cases and reduce the costs associated with liver biopsies.
Furthermore, we propose an approach that could minimise 
the need for liver biopsies further, by using upper cut- offs with 
95% and 98% specificity for the identification of cirrhosis. The 
rationale for this approach is explained in the online supple-
mental discussion. When using the 95% specificity cut- off, the 
proportion of patients needing liver biopsy decreases from 
33% to 19% (figure 3). However, in this approach, 345 of 656 
patients ‘ruled- in’ as having cirrhosis do not have histologically 
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of patients with false positive results, this must be interpreted 
in the light of two factors. First, the limitations of liver biopsy 
could mean that these patients are falsely classified as not having 
cirrhosis histologically. Furthermore, patients without cirrhosis 
on histology and with high NIT values could have equivalent 
risks as patients with cirrhosis on histology. For example, it is 
known from the hepatitis C literature38 that patients without 
cirrhosis on liver biopsy but with a high FIB-4 (>3.25) still had 
a significant risk of developing HCC after hepatitis C treatment, 
demonstrating that NITs can have added benefit beyond the 
histological diagnosis of cirrhosis alone. The rate of false posi-
tive results for cirrhosis can be decreased by choosing cut- offs 
with higher specificity, but this will come at the expense of doing 
more biopsies. Despite this encouraging result, this is an area 
where more information is needed, particularly longitudinal 
data comparing the prognostic value of LSM- VCTE and other 
NITs against histology, and ultimately, the cost effectiveness of 
the various cut- offs would need to be evaluated.
Surprisingly, subgroup analyses showed that the diagnostic 
accuracy of NITs was better in cases with poor biopsy quality. 
This finding is difficult to explain but a similar observation was 
reported previously in a large group of patients screened for clin-
ical trials.29 The use of local biopsy reports as reference standard 
and the well- known observer- dependent variability of biopsy 
interpretation, even among expert pathologists,7 are factors that 
may have contributed to our finding. Spectrum bias was excluded 
as a source of this finding due to a near- identical proportion of 
patients in both the advanced fibrosis and cirrhosis group having 
short biopsies (online supplemental table 5).
Subgroup analysis showed better diagnostic performance 
of NITs in patients with lower BMI,39 40 and patients without 
diabetes, in keeping with other studies.41 42 This effect is likely 
to be primarily driven by BMI as there is thought to be a causal 
association between BMI and T2DM. NIT performance was 
impacted by age, with all NITs performing worse in the younger 
quartile of our study group for advanced fibrosis, but the trend 
was reversed for cirrhosis where NITs performed better in those 
younger than 43 years of age. The age dependence of FIB-4 and 
NFS is expected, as age is one of the parameters included in the 
algorithms, and has indeed been previously described.13 43 It is, 
however, difficult to explain why performance of NITs is better 
in the younger age group for the diagnosis of cirrhosis.
Our study has several strengths, including the large size 
of the IPD study group and composition with prevalence of 
advanced fibrosis of 30%, which makes it relevant to routine 
practice. Furthermore, the proportion of unreliable VCTE 
measurements in our study was 12%, in keeping with the liter-
ature.22 However, we acknowledge some limitations. We did 
not have any data from the USA and very few studies from 
Australia, so the results could not be globally applicable, due to 
differences in BMI across study populations. In addition, due 
to the nature of our study, we had to use the locally provided 
histology results possibly introducing bias. Furthermore, we 
covered a large chronological period, during which LSM- 
VCTE application underwent significant changes, initially with 
the introduction of the XL probe, followed by the advice to 
measure skin- to- capsule distance (SCD) and the introduction 
of the Automatic Probe Selection tool. There was therefore 
some heterogeneity in the performance of LSM- VCTE, with 
early studies using only the M probe to assess all patients, while 
only a subset of studies assessed SCD to guide probe selection. 
Furthermore, one third of the included studies was carried out 
in France, as the technology used for LSM by VCTE originates 
from there. Lastly, our data confirm that LSM- VCTE had supe-
rior accuracy to serum- based tests, and this is independent 
of probe type, sex, ALT, AST, and participants’ continent of 
origin. There was, however, some dependence on the presence 
of T2DM, BMI and for the detection of cirrhosis, and we did 
not check for subgroup- specific cut- offs, but these should be 
explored in future studies.
Our study examined some of the most widely available NITs. 
While it cannot be considered exhaustive, it can be regarded as 
the benchmark against which newer NITs can be tested. This is 
particularly important as new tests are continuously being devel-
oped (FibroTest- FibroSURE, ActiTest,44 ELF45). Furthermore, 
newer tests are also needed for patients with ‘at risk’ NASH 
(NASH+F2–3) who would be candidates for clinical trials or 
treatments, once approved therapies become available (FAST 
score,46 NIS4,47 cTAG48).
In conclusion, our study provides further validation of the 
use of sequential combination of FIB-4 and LSM- VCTE to rule 
out patients with NAFLD and advanced fibrosis who can be 
managed in primary care. We have shown how the use of upper 
cut- offs to rule in cirrhosis in combination with lower cut- offs to 
Table 5 Diagnostic performance of combinations of NAFLD (non- alcoholic fatty liver disease) Fibrosis Score (NFS) and liver stiffness measurement 
(LSM) by vibration controlled transient elastography (VCTE), and Fibrosis-4 Index (FIB-4) and LSM by VCTE tests to diagnose patients with advanced 
fibrosis
FIB-4 & LSM by VCTE
(n=5159)
NFS & LSM by VCTE
(n=3094)
FIB-4 & LSM by VCTE
(n=5159)
NFS & LSM by VCTE
(n=3094)
FIB-4 & LSM by 
VCTE (n=5159)
NFS & LSM by VCTE 
(n=3094)
Advanced fibrosis, % 30 28 30 28 30 28
Thresholds for blood- based NIT <0.88, ≥2.31* <−2.55, ≥0.28* <1.3, ≥2.67† <−1.455, ≥0.676† <1.3, ≥2.67† <−1.455, ≥0.676†
Thresholds for LSM by VCTE, kPa <7.4, ≥12.1* <7.4, ≥12.1* <7.9, ≥9.6† <7.9, ≥9.6† <8.0, ≥10.0† <8.0, ≥10.0†
Sensitivity, % 80 (77–83) 77 (74–81) 67 (64–69) 65 (62–68) 66 (63–68) 64 (62–67)
Specificity, % 81 (79–83) 83 (81–85) 85 (84–87) 86 (84–88) 86 (84–87) 86 (84–88)
PPV, % 62 (60–65) 61 (58–64) 66 (64–68) 63 (61–67) 66 (64–68) 64 (61–67)
NPV, % 91 (90–92) 91 (89–93) 86 (85–87) 87 (85–88) 86 (85–87) 86 (85–88)
Indeterminate, % 18 (17–19) 20 (18–21) 5 (4–5) 5 (5–6) 5 (4–6) 5 (5–6)
Misclassification, % 16 (14–17) 15 (13–17) 19 (18–21) 19 (17–21) 19 (18–20) 19 (17–21)
Patients undergoing LSM by VCTE, % 51 (50–53) 56 (54–59) 34 (32–35) 38 (36–40) 34 (33–35) 38 (37–40)
95% CIs were estimated with 500 bootstrap replicates.
*Thresholds were determined from the individual patient data study group as corresponding to 90% sensitivity (lower value) and 90% specificity (upper value)
†Threshold were determined from the literature. For LSM by VCTE, a threshold pair yielding the highest sensitivity and specificity while having the smallest proportion of indeterminate cases in 
diagnosing advanced fibrosis was chosen.
NIT, non- invasive test; NPV, negative predictive value; PPV, positive predictive value.
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rule out advanced fibrosis can lead to a reduction in the number 
of patients who would need to undergo liver biopsy.
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